It is conceivable that ER signaling may regulate ACBD3 in breast cancer expression, but that FOXA1 contributes to the reprogramming of ER binding and signaling in breast cancer [74], cancelling out the negative impact of GNST and 17βE2-mediated ER transcriptional repression, explaining why decreased distant metastasis-free survival was observed in ER+ patients when ACBD3 expression was high. The gene discussed is ACBD3; the disease is breast carcinoma.